#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians treating neurodegenerative disease patients should understand patient attitudes toward CBD because patients may already be using or considering it despite limited clinical evidence, which requires informed counseling about potential benefits and risks. This data on patient perspectives helps clinicians anticipate treatment discussions and address misconceptions about CBD’s neuroprotective claims with evidence-based guidance. Knowing patient preferences for CBD can inform shared decision-making conversations and identify gaps between patient expectations and current clinical evidence in neurodegenerative disease management.
This study examined attitudes and perceptions regarding cannabidiol (CBD) use among Bulgarian patients with neurodegenerative diseases, building on preclinical evidence suggesting CBD’s potential neuroprotective mechanisms through oxidative stress reduction and neuroinflammation attenuation. Understanding patient perspectives on CBD is clinically relevant as neurodegenerative conditions like Parkinson’s disease and amyotrophic lateral sclerosis currently lack disease-modifying treatments, making patients increasingly interested in complementary approaches. The findings from this patient population can inform clinicians about awareness, expectations, and barriers to CBD use in their own neurodegenerative disease populations, particularly in regions where cannabis-based therapeutics remain less integrated into standard care. As CBD research advances and regulatory pathways evolve in Europe and globally, clinicians should be prepared to discuss realistic evidence, appropriate expectations, and safety considerations with patients who inquire about CBD for neurodegeneration. Clinicians caring for neurodegenerative disease patients should engage proactively with patient attitudes toward CBD, acknowledging legitimate interest while emphasizing the gap between promising preclinical data and currently limited clinical evidence in humans.
“The preclinical data on CBD’s neuroprotective mechanisms are intriguing from a mechanistic standpoint, but we need to be honest with patients that these are laboratory findings so far – we simply don’t yet have the rigorous human trials that would allow me to recommend CBD as a disease-modifying agent for neurodegenerative conditions, and patient attitudes in surveys don’t substitute for clinical evidence.”
💊 While preclinical evidence suggests cannabidiol may offer neuroprotective effects through oxidative stress and neuroinflammation pathways, the translation of these mechanistic findings to meaningful clinical benefit in neurodegenerative diseases remains unproven in most conditions. Patient attitudes and willingness to use CBD documented in surveys like this Bulgarian cohort likely reflect both genuine hope based on preliminary data and exposure to industry marketing that may outpace the current evidence base. Clinicians should recognize that patient interest in CBD use is real and warrants respectful discussion rather than dismissal, but this must be paired with honest communication about the limited clinical trial data in most neurodegenerative conditions and the potential for CBD to interact with existing medications or delay pursuit of proven therapies. Until robust efficacy and safety data emerge from well-designed clinical trials in specific neurodegenerative populations, providers should document patient requests for CBD, discuss realistic expectations, and maintain
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
